ExoSTING affords selective agonism of the STING pathway in tumor resident APC that results in improved potency, reduced systemic toxicity and enhanced T-cell responses, and highlight the potential of our exosome engineering technology as an impactful therapeutic platform. Here, STING1 is linked to neoplasm.